The main focus of the research group is in translational research in gynaecological cancers. In particular biomarker discovery and development (specifically immunological markers) in ovarian and endometrial cancers. The biomarkers are now in the process of being tested for diagnosis and surgical prognosis. The concept of predicting surgical outcome in ovarian cancer is a step in developing personalised medicine and providing patients with best care possible.
Recent advances in oncolgy have improved survival in patients with cancer but research into surgery may have additional benefits for the patient. Clinical research into optimal treatment of cervival preinvasive lesions has been a focus. We have shown that clear margins of resection has a significant effect on reducing risk of recurrence from preinvasive disease.
et al., 2023, Impact of Multiple COVID-19 Waves on Gynaecological Cancer Services in the UK, Cancers, Vol:15
et al., 2023, British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer, Cancers, Vol:15
et al., 2022, An integrated clinical-MR radiomics model to estimate survival time in patients with endometrial cancer, Journal of Magnetic Resonance Imaging, ISSN:1053-1807
et al., 2022, The use of biomarkers to stratify surgical care in women with ovarian cancer, Bjog-an International Journal of Obstetrics and Gynaecology, Vol:129, ISSN:1470-0328, Pages:E66-E74
et al., 2022, Considerations for mulitmodal prehabilitation in women with gynaecological cancers: a scoping review using realist principles, Bmc Women's Health, Vol:22, ISSN:1472-6874, Pages:1-35